Acura Pharmaceuticals, Inc.
ACUR
$0.00
$0.00-25.00%
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -44.87% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.87% | -- | -- | -- | -- |
| Cost of Revenue | -11.34% | -- | -- | -- | -- |
| Gross Profit | -71.85% | -- | -- | -- | -- |
| SG&A Expenses | -10.43% | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.87% | -- | -- | -- | -- |
| Operating Income | -457.42% | -- | -- | -- | -- |
| Income Before Tax | -42.10% | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.10% | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.10% | -- | -- | -- | -- |
| EBIT | -457.42% | -- | -- | -- | -- |
| EBITDA | -314.08% | -- | -- | -- | -- |
| EPS Basic | -12.00% | -- | -- | -- | -- |
| Normalized Basic EPS | -657.69% | -- | -- | -- | -- |
| EPS Diluted | -25.94% | -- | -- | -- | -- |
| Normalized Diluted EPS | -629.63% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 42.45% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 42.25% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |